DE60226956D1 - Verstärktes krebs-gen wip1 - Google Patents

Verstärktes krebs-gen wip1

Info

Publication number
DE60226956D1
DE60226956D1 DE60226956T DE60226956T DE60226956D1 DE 60226956 D1 DE60226956 D1 DE 60226956D1 DE 60226956 T DE60226956 T DE 60226956T DE 60226956 T DE60226956 T DE 60226956T DE 60226956 D1 DE60226956 D1 DE 60226956D1
Authority
DE
Germany
Prior art keywords
wip1
reinforced
cancer
prevention
cancer gen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60226956T
Other languages
English (en)
Inventor
Jing Li
Scott Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE60226956D1 publication Critical patent/DE60226956D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60226956T 2001-02-14 2002-02-12 Verstärktes krebs-gen wip1 Expired - Fee Related DE60226956D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26836201P 2001-02-14 2001-02-14
PCT/US2002/003991 WO2002064838A2 (en) 2001-02-14 2002-02-12 Amplified cancer gene wip1

Publications (1)

Publication Number Publication Date
DE60226956D1 true DE60226956D1 (de) 2008-07-17

Family

ID=23022645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226956T Expired - Fee Related DE60226956D1 (de) 2001-02-14 2002-02-12 Verstärktes krebs-gen wip1

Country Status (6)

Country Link
US (1) US20030032027A1 (de)
EP (1) EP1370693B1 (de)
AT (1) ATE397673T1 (de)
CA (1) CA2438420A1 (de)
DE (1) DE60226956D1 (de)
WO (1) WO2002064838A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037360A1 (en) * 2002-03-22 2005-02-17 Government Of The United States Of America Materials and methods for inhibiting wip1
WO2004112575A2 (en) * 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
US9040491B2 (en) * 2006-08-30 2015-05-26 The Trustees Of The University Of Pennsylvania Compositions, methods and kits based on small nuclear RNAs
US8740762B2 (en) * 2007-04-05 2014-06-03 Vanderbilt University Specific inhibition of cPLA2 enhances the efficacy of radiotherapy
US20100256098A1 (en) * 2007-08-31 2010-10-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
GB201220924D0 (en) * 2012-11-21 2013-01-02 Cancer Res Inst Royal Materials and methods for determining susceptibility or predisposition to cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5516663A (en) * 1990-01-26 1996-05-14 Abbott Laboratories Ligase chain reaction with endonuclease IV correction and contamination control
AU754047B2 (en) * 1998-02-25 2002-10-31 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Tumor tissue microarrays for rapid molecular profiling
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies

Also Published As

Publication number Publication date
WO2002064838A2 (en) 2002-08-22
ATE397673T1 (de) 2008-06-15
CA2438420A1 (en) 2002-08-22
EP1370693B1 (de) 2008-06-04
WO2002064838A3 (en) 2003-10-16
EP1370693A2 (de) 2003-12-17
US20030032027A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2003079982A3 (en) Gene amplification in cancer
WO2008008315A3 (en) Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
WO2004046332A3 (en) Amplified genes involved in cancer
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
ATE538215T1 (de) Expressionsprofil von prostatakarzinom
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003100000A3 (en) Amplification and overexpression of oncogenes
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2003064593A3 (en) Antigen panels and methods of using the same
DE60226956D1 (de) Verstärktes krebs-gen wip1
EA200501197A1 (ru) Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1
WO2003054512A3 (en) Identification of an amplified gene and target for drug intervention
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2003083102A3 (en) Cancer associated protein phosphatases and their uses
WO2004112575A3 (en) Gene amplification and overexpression in cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee